Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial On Schedule

Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company’s two late-stage obesity product candidates.

More: continued here

Filed under: Obesity / Weight Loss / Fitness on July 16th, 2008